Clinical Trial Update: A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anlotinib with or without a PD-1 antibody for unresectable high-grade chondrosarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chondrosarcoma

Drugs mentioned

• Anlotinib (anlotinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Chondrosarcoma | Phase 2 | Status: UNKNOWN